{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:13:41Z","timestamp":1790792021706,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7913","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2022,6,9]]},"DOI":"10.1038\/s41586-022-04797-9","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:04:46Z","timestamp":1654085086000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Combination anti-HIV antibodies provide sustained virological suppression"],"prefix":"10.1038","volume":"606","author":[{"given":"Michael C.","family":"Sneller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-202X","authenticated-orcid":false,"given":"Jana","family":"Blazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Shawn","family":"Justement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke D.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gittens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jekaterina","family":"Tolstenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-0065","authenticated-orcid":false,"given":"Genevieve","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel F.","family":"Schneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Proschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Benko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1727-8693","authenticated-orcid":false,"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0592-8564","authenticated-orcid":false,"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Fauci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Moir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-7340","authenticated-orcid":false,"given":"Tae-Wook","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"4797_CR1","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks, S. G., Lewin, S. R. & Havlir, D. V. The end of AIDS: HIV infection as a chronic disease. Lancet 382, 1525\u20131533 (2013).","journal-title":"Lancet"},{"key":"4797_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.3152","volume":"16","author":"TW Chun","year":"2015","unstructured":"Chun, T. W., Moir, S. & Fauci, A. S. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat. Immunol. 16, 584\u2013589 (2015).","journal-title":"Nat. Immunol."},{"key":"4797_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/jama.2019.5397","volume":"322","author":"TW Chun","year":"2019","unstructured":"Chun, T. W., Eisinger, R. W. & Fauci, A. S. Durable control of HIV infection in the absence of antiretroviral therapy: opportunities and obstacles. JAMA 322, 27\u201328 (2019).","journal-title":"JAMA"},{"key":"4797_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41586-019-1841-8","volume":"576","author":"T Ndung\u2019u","year":"2019","unstructured":"Ndung\u2019u, T., McCune, J. M. & Deeks, S. G. Why and where an HIV cure is needed and how it might be achieved. Nature 576, 397\u2013405 (2019).","journal-title":"Nature"},{"key":"4797_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","volume":"27","author":"LB Cohn","year":"2020","unstructured":"Cohn, L. B., Chomont, N. & Deeks, S. G. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe 27, 519\u2013530 (2020).","journal-title":"Cell Host Microbe"},{"key":"4797_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","volume":"48","author":"S Sengupta","year":"2018","unstructured":"Sengupta, S. & Siliciano, R. F. Targeting the latent reservoir for HIV-1. Immunity 48, 872\u2013895 (2018).","journal-title":"Immunity"},{"key":"4797_CR7","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94, 13193\u201313197 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4797_CR8","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295\u20131300 (1997).","journal-title":"Science"},{"key":"4797_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291\u20131295 (1997).","journal-title":"Science"},{"key":"4797_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cell.2020.03.005","volume":"181","author":"DM Margolis","year":"2020","unstructured":"Margolis, D. M. et al. Curing HIV: seeking to target and clear persistent infection. Cell 181, 189\u2013206 (2020).","journal-title":"Cell"},{"key":"4797_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0140-6736(20)30264-6","volume":"395","author":"SR Lewin","year":"2020","unstructured":"Lewin, S. R. & Rasmussen, T. A. Kick and kill for HIV latency. Lancet 395, 844\u2013846 (2020).","journal-title":"Lancet"},{"key":"4797_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells, S. et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med. 382, 1112\u20131123 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4797_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin, C. et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 382, 1124\u20131135 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4797_CR14","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","volume":"396","author":"ET Overton","year":"2021","unstructured":"Overton, E. T. et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 396, 1994\u20132005 (2021).","journal-title":"Lancet"},{"key":"4797_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey, M., Klein, F. & Nussenzweig, M. C. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat. Med. 25, 547\u2013553 (2019).","journal-title":"Nat. Med."},{"key":"4797_CR16","doi-asserted-by":"publisher","first-page":"eaaz2686","DOI":"10.1126\/scitranslmed.aaz2686","volume":"11","author":"BF Haynes","year":"2019","unstructured":"Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. 11, eaaz2686 (2019).","journal-title":"Sci. Transl. Med."},{"key":"4797_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","volume":"69","author":"L Gama","year":"2018","unstructured":"Gama, L. & Koup, R. A. New-generation high-potency and designer antibodies: role in HIV-1 treatment. Annu. Rev. Med. 69, 409\u2013419 (2018).","journal-title":"Annu. Rev. Med."},{"key":"4797_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.chom.2017.07.010","volume":"22","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. & Martin, M. A. Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1. Cell Host Microbe 22, 207\u2013216 (2017).","journal-title":"Cell Host Microbe"},{"key":"4797_CR19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4797_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"4797_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"4797_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556\u2013560 (2016).","journal-title":"Nature"},{"key":"4797_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"4797_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"4797_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"CL Lu","year":"2016","unstructured":"Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001\u20131004 (2016).","journal-title":"Science"},{"key":"4797_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"4797_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med. 26, 222\u2013227 (2020).","journal-title":"Nat. Med."},{"key":"4797_CR28","doi-asserted-by":"publisher","first-page":"eaan8848","DOI":"10.1126\/scitranslmed.aan8848","volume":"9","author":"MC Sneller","year":"2017","unstructured":"Sneller, M. C. et al. A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci. Transl. Med. 9, eaan8848 (2017).","journal-title":"Sci. Transl. Med."},{"key":"4797_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","volume":"62","author":"SG Deeks","year":"2011","unstructured":"Deeks, S. G. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141\u2013155 (2011).","journal-title":"Annu. Rev. Med."},{"key":"4797_CR30","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/cyto.a.22625","volume":"87","author":"S Van Gassen","year":"2015","unstructured":"Van Gassen, S. et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A 87, 636\u2013645 (2015).","journal-title":"Cytometry A"},{"key":"4797_CR31","doi-asserted-by":"publisher","first-page":"e20201214","DOI":"10.1084\/jem.20201214","volume":"218","author":"Y Nishimura","year":"2021","unstructured":"Nishimura, Y. et al. Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. J. Exp. Med. 218, e20201214 (2021).","journal-title":"J. Exp. Med."},{"key":"4797_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.1255512","volume":"345","author":"DH Barouch","year":"2014","unstructured":"Barouch, D. H. & Deeks, S. G. Immunologic strategies for HIV-1 remission and eradication. Science 345, 169\u2013174 (2014).","journal-title":"Science"},{"key":"4797_CR33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471\u2013482 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"4797_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","volume":"48","author":"PD Kwong","year":"2018","unstructured":"Kwong, P. D. & Mascola, J. R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855\u2013871 (2018).","journal-title":"Immunity"},{"key":"4797_CR35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179\u20131188 (2018).","journal-title":"Nat. Immunol."},{"key":"4797_CR36","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.immuni.2021.08.007","volume":"54","author":"DR Collins","year":"2021","unstructured":"Collins, D. R. et al. Functional impairment of HIV-specific CD8+ T cells precedes aborted spontaneous control of viremia. Immunity 54, 2372\u20132384 (2021).","journal-title":"Immunity"},{"key":"4797_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/ni.3161","volume":"16","author":"SA Migueles","year":"2015","unstructured":"Migueles, S. A. & Connors, M. Success and failure of the cellular immune response against HIV-1. Nat. Immunol. 16, 563\u2013570 (2015).","journal-title":"Nat. Immunol."},{"key":"4797_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"4797_CR39","doi-asserted-by":"publisher","first-page":"e1006792","DOI":"10.1371\/journal.ppat.1006792","volume":"14","author":"KE Clarridge","year":"2018","unstructured":"Clarridge, K. E. et al. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 14, e1006792 (2018).","journal-title":"PLoS Pathog."},{"key":"4797_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-019-0898-8","volume":"566","author":"KM Bruner","year":"2019","unstructured":"Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature 566, 120\u2013125 (2019).","journal-title":"Nature"},{"key":"4797_CR41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/jcm.32.3.732-739.1994","volume":"32","author":"LE Myers","year":"1994","unstructured":"Myers, L. E., McQuay, L. J. & Hollinger, F. B. Dilution assay statistics. J. Clin. Microbiol. 32, 732\u2013739 (1994).","journal-title":"J. Clin. Microbiol."},{"key":"4797_CR42","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H. S. et al. Comprehensive assessment of T-cell receptor \u03b2-chain diversity in \u03b1\u03b2 T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"4797_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).","journal-title":"Nat. Commun."},{"key":"4797_CR44","doi-asserted-by":"publisher","unstructured":"Snyder, T. M. et al. Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels. Preprint at MedRxiv https:\/\/doi.org\/10.1101\/2020.07.31.20165647 (2020).","DOI":"10.1101\/2020.07.31.20165647"},{"key":"4797_CR45","unstructured":"ImmunoMind Team. immunarch: an R package for painless bioinformatics analysis of T-cell and B-cell immune repertoires (version 0.6.7) (Zenodo, 2019)."},{"key":"4797_CR46","doi-asserted-by":"publisher","first-page":"D339","DOI":"10.1093\/nar\/gky1006","volume":"47","author":"R Vita","year":"2019","unstructured":"Vita, R. et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 47, D339\u2013D343 (2019).","journal-title":"Nucleic Acids Res."},{"key":"4797_CR47","doi-asserted-by":"publisher","first-page":"D419","DOI":"10.1093\/nar\/gkx760","volume":"46","author":"M Shugay","year":"2018","unstructured":"Shugay, M. et al. VDJdb: a curated database of T-cell receptor sequences with known antigen specificity. Nucleic Acids Res. 46, D419\u2013D427 (2018).","journal-title":"Nucleic Acids Res."},{"key":"4797_CR48","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1093\/bioinformatics\/btx286","volume":"33","author":"N Tickotsky","year":"2017","unstructured":"Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E. & Friedman, N. McPAS-TCR: a manually curated catalogue of pathology-associated T cell receptor sequences. Bioinformatics 33, 2924\u20132929 (2017).","journal-title":"Bioinformatics"},{"key":"4797_CR49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/bioinformatics\/btz614","volume":"36","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. PIRD: pan immune repertoire database. Bioinformatics 36, 897\u2013903 (2020).","journal-title":"Bioinformatics"},{"key":"4797_CR50","unstructured":"Kassambara, A. ggpubr: \u2018ggplot2\u2019 based publication ready plots. R package version 0.1.7 (2018)."},{"key":"4797_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","volume":"25","author":"S L\u00ea","year":"2008","unstructured":"L\u00ea, S., Josse, J. & Husson, F. FactoMineR: an R package for multivariate analysis. J. Stat. Softw. 25, 1\u201318 (2008).","journal-title":"J. Stat. Softw."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04797-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:22:36Z","timestamp":1733937756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-04797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":51,"journal-issue":{"issue":"7913","published-print":{"date-parts":[[2022,6,9]]}},"alternative-id":["4797"],"URL":"https:\/\/doi.org\/10.1038\/s41586-022-04797-9","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742177223.793593557","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C.N. is listed as an inventor for patents on 3BNC117 (PTC\/US2012\/038400) and 10-1074 (PTC\/US2013\/065696); 3BNC117 and 10-1074 are licensed to Gilead Sciences by Rockefeller University from which M.C.N. has received payments. M.C.N. is a member of the Scientific Advisory Boards of Celldex Therapeutics, Walking Fish Therapeutics and Frontier Biotechnologies. M.C.N. had no control over the direction and ultimately the reporting of the clinical portion of the research while holding their financial interests. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}